Francesco Draetta

Commonfund Capital, Inc (Commonfund Capital) is a private equity and venture capital subsidiary of Commonfund Holding Co., Inc founded in 1988. The firm is headquartered in Wilton, Connecticut with additional offices in New York, California, London & China.

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

Beta Bionics, Inc. operates a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the autonomous bionic pancreas. The company was founded by Edward R. Damiano in October 21, 2015 and is headquartered in Boston, MA.

Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland.

Omega Alpha SPAC is a blank check company. Its purposes effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Otello Stampacchia, Michelle Doig, Francesco Draetta and Vincent Ossipow on October 26, 2020 and is headquartered in Boston, MA.

NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.